Search

Author/Creator McDermott, David F

1. 2022-RA-588-ESGO Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY-1. (20th October 2022)

Authors:
Vaishampayan, Ulka; Tomczak, Piotr; Muzaffar, Jameel; Winer, Ira; Rosen, Seth D; Hoimes, Christopher J; Chauhan, Aman; Spreafico, Anna; Lewis, Karl D; Bruno, Debora S; Dumas, Olivier; McDermott, David F; Strauss, James F; Chu, Quincy Siu-Chung; Gilbert, Lucy; Chaudhry, Arvind; Rege, Jessicca; Bon...
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 2
Page Start:
A241
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2). (4th November 2015)

Authors:
Erbe, Amy K; Wang, Wei; Kim, Kyung Mann; Carmichael, Laskeesha; Gallendberger, MIkayla; Hess, Dustin; Mendonca, Eneida A; Song, Yiqiang; Hank, Jacquelyn A; Chen, Su-Chun; Signoretti, Sabina; Atkins, Michael B; Carlson, Alexander; Mier, James; Panka, David; McDermott, David F; Sondel, Paul M
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Issue 10189 (15th June 2019)

Authors:
Rini, Brian I; Powles, Thomas; Atkins, Michael B; Escudier, Bernard; McDermott, David F; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begoña; Por...
Journal:
Lancet
Issue:
Volume 393:Issue 10189(2019)
Page Start:
2404
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Issue 3 (March 2018)

Authors:
Atkins, Michael B; Plimack, Elizabeth R; Puzanov, Igor; Fishman, Mayer N; McDermott, David F; Cho, Daniel C; Vaishampayan, Ulka; George, Saby; Olencki, Thomas E; Tarazi, Jamal C; Rosbrook, Brad; Fernandez, Kathrine C; Lechuga, Mariajose; Choueiri, Toni K
Journal:
Lancet oncology
Issue:
Volume 19:Issue 3(2018)
Page Start:
405
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. Issue 3 (18th March 2022)

Authors:
Motzer, Robert J; Choueiri, Toni K; McDermott, David F; Powles, Thomas; Vano, Yann-Alexandre; Gupta, Saurabh; Yao, Jin; Han, Celine; Ammar, Ron; Papillon-Cavanagh, Simon; Saggi, Shruti S; McHenry, M Brent; Ross-Macdonald, Petra; Wind-Rotolo, Megan
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 3(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Issue 7 (July 2016)

Authors:
Choueiri, Toni K; Escudier, Bernard; Powles, Thomas; Tannir, Nizar M; Mainwaring, Paul N; Rini, Brian I; Hammers, Hans J; Donskov, Frede; Roth, Bruce J; Peltola, Katriina; Lee, Jae Lyun; Heng, Daniel Y C; Schmidinger, Manuela; Agarwal, Neeraj; Sternberg, Cora N; McDermott, David F; Aftab, Dana T;...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 7(2016:Jul.)
Page Start:
917
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Issue 11 (November 2016)

Authors:
Hodi, F Stephen; Chesney, Jason; Pavlick, Anna C; Robert, Caroline; Grossmann, Kenneth F; McDermott, David F; Linette, Gerald P; Meyer, Nicolas; Giguere, Jeffrey K; Agarwala, Sanjiv S; Shaheen, Montaser; Ernstoff, Marc S; Minor, David R; Salama, April K; Taylor, Matthew H; Ott, Patrick A; Horak, ...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 11(2016:Nov.)
Page Start:
1558
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. (11th March 2019)

Authors:
Atkins, Michael B; Tarhini, Ahmad; Rael, Michael; Gupte-Singh, Komal; O'Brien, Elliott; Ritchings, Corey; Rao, Sumati; McDermott, David F
Journal:
Immunotherapy
Issue:
Volume 11:Number 7(2019)
Page Start:
617
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗